- Home
- RNP vs RCUS Comparison
RNP vs RCUS Comparison
Compare RNP & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- RCUS
- Stock Information
- Founded
- RNP 2003
- RCUS 2015
- Country
- RNP United States
- RCUS United States
- Employees
- RNP N/A
- RCUS N/A
- Industry
- RNP Investment Managers
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- RNP Finance
- RCUS Health Care
- Exchange
- RNP Nasdaq
- RCUS Nasdaq
- Market Cap
- RNP 1.0B
- RCUS 1.2B
- IPO Year
- RNP N/A
- RCUS 2018
- Fundamental
- Price
- RNP $21.94
- RCUS $8.17
- Analyst Decision
- RNP
- RCUS Strong Buy
- Analyst Count
- RNP 0
- RCUS 10
- Target Price
- RNP N/A
- RCUS $29.50
- AVG Volume (30 Days)
- RNP 117.6K
- RCUS 907.7K
- Earning Date
- RNP 01-01-0001
- RCUS 05-07-2025
- Dividend Yield
- RNP 7.94%
- RCUS N/A
- EPS Growth
- RNP N/A
- RCUS N/A
- EPS
- RNP N/A
- RCUS N/A
- Revenue
- RNP N/A
- RCUS $258,000,000.00
- Revenue This Year
- RNP N/A
- RCUS N/A
- Revenue Next Year
- RNP N/A
- RCUS $28.07
- P/E Ratio
- RNP N/A
- RCUS N/A
- Revenue Growth
- RNP N/A
- RCUS 120.51
- 52 Week Low
- RNP $15.52
- RCUS $8.02
- 52 Week High
- RNP $21.27
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- RNP 55.14
- RCUS 30.17
- Support Level
- RNP $21.67
- RCUS $8.02
- Resistance Level
- RNP $22.14
- RCUS $9.19
- Average True Range (ATR)
- RNP 0.30
- RCUS 0.46
- MACD
- RNP 0.01
- RCUS 0.01
- Stochastic Oscillator
- RNP 78.72
- RCUS 7.46
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.